Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation.

Meier, David; Akodad, Mariama; Tzimas, Georgios; Muller, Olivier; Cheung, Anson; Wood, David A; Blanke, Philipp; Sathananthan, Janarthanan; Praz, Fabien; Boone, Robert H; Webb, John G (2023). Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation. Current cardiology reports, 25(10), pp. 1361-1371. Springer 10.1007/s11886-023-01954-y

Text s11886-023-01954-y.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Author holds Copyright Download (680kB)

PURPOSE OF REVIEW

Mitral and tricuspid regurgitation represents a clinical challenge. They are associated with a poor prognosis, and many patients are not eligible for conventional surgery. Transcatheter therapies have been the focus of numerous studies and devices over the past decade. Here, we provide a summary of current options for transcatheter treatment of these 2 entities.

RECENT FINDINGS

Recent studies have demonstrated the benefits of edge-to-edge repair for increasing numbers of patients. Encouraging early results with transcatheter valve replacement are also becoming available. To date, transcatheter edge-to-edge repair is currently the first-line transcatheter treatment for both mitral and tricuspid regurgitation for many patients who are not candidates for surgery. A number of transcatheter replacement devices are under development and clinical investigation but, for the most part, their current use is limited to compassionate cases or clinical trials.

Interest & Impact

Downloads

1 since deposited on 13 Sep 2023
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item